WallStSmart

DexCom Inc (DXCM)vsInspira Technologies Oxy BHN Ltd (IINN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 1719346% more annual revenue ($4.97B vs $289,000). DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 74/100 (B).

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

IINN

Avoid

15

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

IINN0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

IINN4 concerns · Avg: 3.8/10
Price/BookValuation
12.7x4/10

Trading at 12.7x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$18.91M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : IINN

IINN has a balanced fundamental profile.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : IINN

The primary concerns for IINN are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

DXCM profiles as a mature stock while IINN is a value play — different risk/reward profiles.

IINN carries more volatility with a beta of 2.16 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (74/100 vs 15/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Inspira Technologies Oxy BHN Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Inspira Technologies Oxy BHN Ltd., a specialty medical device company, is engaged in the research, development, manufacture and commercialization of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory insufficiency. The company is headquartered in Ra'annana, Israel.

Want to dig deeper into these stocks?